Table 2 Multiple Cox proportional hazards regression analysis of factors associated with achieving optimum viral load suppression among noncirrhotic patients, stratified by sex and age group.
N of eventsa (N = 230) | Adjusted HR | 95% CI | p valueb | |
|---|---|---|---|---|
HCV genotype | ||||
6 (ref) | 50 (14.3) | 1.000 | – | – |
1 | 162 (46.3) | 1.151 | 0.963–1.432 | 0.153 |
2 | 3 (0.9) | 1.854 | 1.142–3.702 | 0.020 |
3 | 135 (38.6) | 0.986 | 0.797–1.241 | 0.902 |
IL-28B genotype | ||||
CT + TT (ref) | 84 (24.0) | 1.000 | – | – |
CC | 266 (76.0) | 0.002 | 0.000–0.007 | 0.001 |
HIV coinfection | ||||
No (ref) | 208 (59.4) | 1.000 | – | – |
Yes | 142 (40.6) | 1.128 | 0.935–1.359 | 0.212 |
Previous interferon treatment exposure | ||||
Treatment-experienced (ref) | 70 (20.0) | 1.000 | – | – |
Treatment-naïve | 280 (80.0) | 4.7E + 4 | 3.8E + 3–3.5E + 7 | 0.001 |
Injection drug use | ||||
No (ref) | 187 (53.4) | 1.000 | – | – |
Yes | 163 (46.6) | 1.232 | 1.027–1.487 | 0.023 |
Use of concomitant medications | ||||
No (ref) | 41 (11.7) | 1.000 | – | – |
Yes | 309 (88.3) | 0.918 | 0.659–1.358 | 0.630 |
Comorbidities | ||||
No (ref) | 302 (86.3) | 1.000 | – | – |
Yes | 48 (13.7) | 0.961 | 0.703–1.247 | 0.768 |
IL-28B genotypes * Log Time | – | 0.144 | 0.068–0.221 | 0.001 |
Previous interferon treatment exposure * Log time | – | 0.044 | 0.007–0.091 | 0.001 |
